Holen Sie sich die Stockscreener-App
29.66
0.20%
0.06
Handel nachbörslich:
29.75
0.09
+0.30%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt ALKS?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$29.60
Offen:
$29.73
24-Stunden-Volumen:
2.79M
Relative Volume:
1.24
Marktkapitalisierung:
$4.90B
Einnahmen:
$1.51B
Nettoeinkommen (Verlust:
$333.35M
KGV:
15.21
EPS:
1.95
Netto-Cashflow:
$315.22M
1W Leistung:
+4.95%
1M Leistung:
+4.29%
6M Leistung:
-1.07%
1J Leistung:
+4.36%
1-Tages-Spanne:
$29.58
$30.47
1-Wochen-Bereich:
$27.50
$30.47
52-Wochen-Spanne:
$25.16
$36.45
Alkermes Plc Stock (ALKS) Company Profile
Firmenname
Alkermes Plc
Sektor
Telefon
00-353-1-772-8000
Adresse
CONNAUGHT HOUSE, DUBLIN 4
Vergleichen Sie ALKS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ALKS
Alkermes Plc
|
29.66 | 4.89B | 1.51B | 333.35M | 315.22M | 1.95 |
|
ZTS
Zoetis Inc
|
127.17 | 55.90B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
16.31 | 51.72B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
9.91 | 44.71B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
32.01 | 37.30B | 16.88B | 666.71M | 251.19M | 0.6132 |
|
RGC
Regencell Bioscience Holdings Ltd
|
45.79 | 20.48B | 0 | -5.87M | -767.30K | -0.45 |
Alkermes Plc Stock (ALKS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-11-11 | Eingeleitet | Truist | Buy |
| 2025-09-26 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2025-09-03 | Eingeleitet | Wells Fargo | Overweight |
| 2025-07-15 | Eingeleitet | Goldman | Buy |
| 2025-06-17 | Hochstufung | UBS | Neutral → Buy |
| 2025-05-28 | Eingeleitet | Needham | Buy |
| 2025-03-13 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2025-03-04 | Hochstufung | UBS | Sell → Neutral |
| 2025-02-11 | Eingeleitet | Deutsche Bank | Buy |
| 2024-11-05 | Hochstufung | Stifel | Hold → Buy |
| 2024-06-17 | Eingeleitet | TD Cowen | Buy |
| 2024-03-19 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-02-20 | Herabstufung | UBS | Neutral → Sell |
| 2023-11-20 | Fortgesetzt | JP Morgan | Neutral |
| 2023-10-24 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2023-10-17 | Eingeleitet | UBS | Neutral |
| 2022-11-03 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2022-10-14 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2022-08-16 | Eingeleitet | Piper Sandler | Neutral |
| 2022-04-22 | Fortgesetzt | Goldman | Buy |
| 2022-04-20 | Eingeleitet | Goldman | Buy |
| 2022-01-27 | Hochstufung | Cantor Fitzgerald | Hold → Overweight |
| 2021-12-01 | Eingeleitet | Citigroup | Neutral |
| 2021-10-07 | Hochstufung | Jefferies | Hold → Buy |
| 2021-09-02 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2020-10-15 | Hochstufung | Mizuho | Neutral → Buy |
| 2020-07-30 | Herabstufung | Goldman | Neutral → Sell |
| 2020-02-14 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2020-02-14 | Bestätigt | H.C. Wainwright | Neutral |
| 2020-02-14 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-02-06 | Eingeleitet | Mizuho | Neutral |
| 2020-01-31 | Hochstufung | Wolfe Research | Underperform → Peer Perform |
| 2019-09-05 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2019-07-15 | Hochstufung | Goldman | Sell → Neutral |
| 2019-05-31 | Eingeleitet | H.C. Wainwright | Neutral |
| 2019-05-01 | Herabstufung | Citigroup | Buy → Neutral |
| 2018-12-19 | Herabstufung | Goldman | Neutral → Sell |
| 2018-12-14 | Eingeleitet | Wolfe Research | Underperform |
| 2018-12-13 | Herabstufung | Credit Suisse | Outperform → Underperform |
| 2018-11-05 | Eingeleitet | Piper Jaffray | Neutral |
| 2018-08-07 | Eingeleitet | Stifel | Hold |
| 2018-06-21 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2018-06-06 | Eingeleitet | B. Riley FBR, Inc. | Buy |
| 2018-05-16 | Hochstufung | Citigroup | Neutral → Buy |
| 2018-05-11 | Eingeleitet | BofA/Merrill | Buy |
Alle ansehen
Alkermes Plc Aktie (ALKS) Neueste Nachrichten
Is Alkermes plc (8AK) stock a momentum leaderJuly 2025 Weekly Recap & Stepwise Swing Trade Plans - ulpravda.ru
Is Alkermes plc stock positioned for digital transformation2025 Growth vs Value & Capital Protection Trade Alerts - ulpravda.ru
Technical Reactions to ALKS Trends in Macro Strategies - Stock Traders Daily
Top Biotech Players REGN, INCY, PTCT Among Participants At J.P.Morgan Healthcare Conference 2026 - RTTNews
How FDA Breakthrough Therapy Status for Alixorexton Will Impact Alkermes (ALKS) Investors - Sahm
What dividend safety score for Alkermes plc stockMarket Sentiment Review & High Yield Equity Trading Tips - ulpravda.ru
Will Alkermes plc stock split attract more investorsJuly 2025 Opening Moves & Free Technical Confirmation Trade Alerts - ulpravda.ru
Race For Avadel Heats Up: Alkermes Raises Offer To Secure $2.37B Deal After Lundbeck Challenge - MSN
Alkermes: Avadel Deal And Vibrance-2 Unlock Upside - Seeking Alpha
Is Alkermes plc stock supported by innovation pipelineGold Moves & Free Accurate Trade Setup Notifications - ulpravda.ru
Is Alkermes plc stock a good choice for value investors2025 Trading Volume Trends & Free Technical Confirmation Trade Alerts - ulpravda.ru
FDA Grants Breakthrough Therapy Designation to ALKS' Narcolepsy Drug - Finviz
Alkermes plc's (NASDAQ:ALKS) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong? - simplywall.st
Why Analysts See The Alkermes (ALKS) Story Shifting After Avadel Deal And Orexin Data - Yahoo Finance
FDA Grants Alixorexton Breakthrough Therapy Designation for Narcolepsy Type 1 - Sleep Review
Is Alkermes plc (8AK) stock a top pick for value investorsTrade Performance Summary & Weekly Breakout Opportunity Watchlist - ulpravda.ru
Is Alkermes (ALKS) Pricing Reflect Its DCF Value Gap And Recent Mixed Returns - Yahoo Finance UK
Alkermes to present at the 44th annual JP Morgan Healthcare Conference - MSN
Alkermes gains FDA breakthrough status for narcolepsy drug - MSN
FDA Grants Breakthrough Therapy Designation to Alixorexton for Narcolepsy Type 1 - HCPLive
Alkermes stock rises after FDA grants Breakthrough Therapy status By Investing.com - Investing.com South Africa
Alkermes stock rises after FDA grants Breakthrough Therapy status - Investing.com
FDA grants breakthrough therapy status to Alkermes’ narcolepsy drug By Investing.com - Investing.com South Africa
Alkermes Gains FDA Breakthrough Status for Narcolepsy Drug - TipRanks
Alkermes plc Granted Breakthrough Therapy Designation for Alixorexton - TradingView — Track All Markets
Alixorexton Granted Breakthrough Therapy Designation by U.S. FDA for the Treatment of Narcolepsy Type 1 - Business Wire
Alkermes Plc (ALKS) Stock Analysis: Unveiling A 55% Upside Potential For Investors - DirectorsTalk Interviews
Deutsche Bank Initiates Coverage of Alkermes (ALKS) with Buy Recommendation - MSN
Alkermes to Host Conference Call to Discuss Financial Results for Quarter Ended June 30, 2013 - AOL.com
Insider Sell: Craig Hopkinson Sells 4,000 Shares of Alkermes PLC (ALKS) - GuruFocus
Alkermes (NASDAQ:ALKS) EVP Sells $112,000.00 in Stock - MarketBeat
J.P. Morgan Healthcare Conference - marketscreener.com
Levels Update: Will Alkermes plc 8AK stock outperform global peersChart Signals & Short-Term Trading Alerts - moha.gov.vn
VIRGINIA RETIREMENT SYSTEMS ET Al Invests $27.04 Million in Alkermes plc $ALKS - MarketBeat
Alkermes to Present at the 44th Annual J.P. Morgan Healthcare Conference - Business Wire
Centessa narcolepsy data not superior to Alkermes, says Stifel - MSN
Trading the Move, Not the Narrative: (ALKS) Edition - Stock Traders Daily
Alkermes plc $ALKS Shares Sold by Rice Hall James & Associates LLC - MarketBeat
Pacer Advisors Inc. Sells 98,825 Shares of Alkermes plc $ALKS - MarketBeat
About the Alkermes Inspiration Grants® Program - CSRwire
Alkermes plc (ALKS) Stock Price History & Data - Traders Union
Why Analysts are Rating Alkermes (ALKS) a Buy - Finviz
Why analysts are rating Alkermes (ALKS) a buy - MSN
15 Most Promising Mid-Cap Healthcare Stocks Under $50 - Insider Monkey
Alkermes plc (NASDAQ:ALKS) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Will Alkermes plc stock benefit from commodity pricesTrade Analysis Summary & Growth Focused Stock Pick Reports - Улправда
Why global investors buy Alkermes plc (8AK) stockEarnings Recap Report & Reliable Volume Spike Alerts - Bölüm Sonu Canavarı
ALKS (Alkermes) Other Current Payables : $0 Mil (As of Sep. 2025) - GuruFocus
Will Alkermes plc (8AK) stock test record highs in 20252025 Performance Recap & Low Risk Growth Stock Ideas - DonanımHaber
Can Alkermes plc stock continue upward trendPortfolio Gains Summary & Comprehensive Market Scan Reports - DonanımHaber
Behavioral Patterns of ALKS and Institutional Flows - Stock Traders Daily
Finanzdaten der Alkermes Plc-Aktie (ALKS)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.37%
1.55%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):